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Orientation of Heparin-binding Sites in Native Vitronectin
ANALYSES OF LIGAND BINDING TO THE PRIMARY GLYCOSAMINOGLYCAN-BINDING SITE INDICATE THAT
PUTATIVE SECONDARY SITES ARE NOT FUNCTIONAL*
(Received for publication, August 18, 1998, and in revised form, October 27, 1998)

Angelia D. Gibson‡, John A. Lamerdin, Ping Zhuang, Kunnumal Baburaj§, Engin H. Serpersu,
and Cynthia B. Peterson¶
From the Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee,
Knoxville, Tennessee 37996

A primary heparin-binding site in vitronectin has been
localized to a cluster of cationic residues near the C terminus of the protein. More recently, secondary binding
sites have been proposed. In order to investigate whether
the binding site originally identified on vitronectin functions as an exclusive and independent heparin-binding
domain, solution binding methods have been used in combination with NMR and recombinant approaches to evaluate ligand binding to the primary site. Evaluation of the
ionic strength dependence of heparin binding to vitronectin according to classical linkage theory indicates that a
single ionic bond is prominent. It had been previously
shown that chemical modification of vitronectin using an
arginine-reactive probe results in a significant reduction
in heparin binding (Gibson, A., Baburaj, K., Day, D. E.,
Verhamme, I., Shore, J. D., and Peterson, C. B. (1997)
J. Biol. Chem. 272, 5112–5121). The label has now been
localized to arginine residues within the cyanogen bromide fragment-(341–380) that contains the primary heparin-binding site on vitronectin. One- and two-dimensional
NMR on model peptides based on this primary heparinbinding site indicate that an arginine residue participates
in the ionic interaction and that other nonionic interactions may be involved in forming a complex with heparin.
A recombinant polypeptide corresponding to the C-terminal 129 amino acids of vitronectin exhibits heparin-binding affinity that is comparable to that of full-length
vitronectin and is equally effective at neutralizing heparin anticoagulant activity. Results from this broad experimental approach argue that the behavior of the primary
site is sufficient to account for the heparin binding activity of vitronectin and support an exposed orientation for
the site in the structure of the native protein.
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Since the discovery of vitronectin in 1967, numerous studies
have been conducted in an effort to characterize the structure
and functions of this plasma and extracellular matrix protein
(1–3). The model of vitronectin that has emerged describes a
multifunctional protein that interacts with a wide variety of
macromolecules to regulate physiological processes, including
complement-mediated cell lysis, cell adhesion, coagulation, and
fibrinolysis. Sequence analysis and binding studies suggest a
domain organization for vitronectin, with its functions mediated through individual elements aligned linearly along the
sequence of the molecule (4 –9).
The work to date supports the assignment of at least three
domains within vitronectin. (i) The N-terminal domain consists
of 44 amino acids that are identical to the circulating protein,
Somatomedin B. Among these 44 amino acids are 8 cysteines
that form 4 disulfide bonds. Binding sites for the anti-fibrinolytic protease inhibitor, PAI-1,1 and for cell-surface receptors
have been localized to this region of vitronectin. The Somatomedin B domain has been expressed in Escherichia coli as a
functional protein that mimics the ability of vitronectin to bind
and stabilize the active conformation of PAI-1 (10, 11). (ii) The
amino acids 131–268 and 269 – 459 of vitronectin share homology with domains found in hemopexin and collagenase (12). (iii)
At the C terminus of vitronectin, a highly charged sequence
interrupts the second hemopexin homology domain. This cationic sequence has been proposed to be the primary binding site
for numerous ligands such as plasminogen, the complement
C7, C8, and C9 components, PAI-1, and the widely administered anticoagulant drug, heparin (4, 5, 13). A working model
depicting the domain arrangement of vitronectin is presented
in Fig. 1.
The interaction between vitronectin and heparin is one of the
most highly researched topics in the vitronectin literature. In
1983, vitronectin was shown to bind heparin-Sepharose (14).
Subsequent studies revealed that vitronectin neutralized heparin anticoagulant activity, suggesting a regulatory role for the
glycoprotein in coagulation (15). A search for the glycosaminoglycan-binding site within vitronectin localized binding activity
to a C-terminal vitronectin fragment produced by digestion
with cyanogen bromide (4). Another group reported that a
fragment corresponding to the C-terminal region of vitronectin
bound heparin in ligand blotting assays and that synthetic
peptides corresponding to the vitronectin residues 347–359
bound biotinylated heparin and diminished heparin activity (5,
16, 17). Also, proteases such as thrombin and plasmin, which
cleave vitronectin within the proposed heparin-binding se-

1
The abbreviations used are: PAI-1, plasminogen activator inhibitor-1; rCTD, recombinant C-terminal domain; HOCGO, 7-hydroxy coumarinyl-3-glyoxal; NOE, nuclear Overhauser effect.
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FIG. 1. Domain arrangement of vitronectin. A working model for the domain arrangement of vitronectin is depicted. The Somatomedin B
domain is shown in blue. The tertiary structure of this domain is stabilized by four disulfide bonds, shown in yellow. The sequence flanking the
Somatomedin B domain (shown in green) contains the RGD cell-binding motif. The hemopexin homology domains are shown in red. The structure
of these regions was loosely based on the known b-structure of the hemopexin C-terminal domain (57, 58). Interrupting the second hemopexin
domain, the heparin-binding sequence is shown in pink and exposed on the surface of the molecule. A disulfide bond is known to exist between the
two hemopexin domains. This is depicted in yellow. Two free sulfhydryls (shown in yellow) are buried within the interior of vitronectin (29); one
of these has been identified in this laboratory as Cys-411. (Two cysteines are present in human plasma-derived vitronectin at positions 411 and
453. It is well established that one of these must participate in disulfide bond formation with a cysteine N-terminal to the endogenous protease
cleavage site at position 379, since the C-terminal proteolytic fragment is only released under denaturing conditions.)

quence, disrupt heparin binding to the protein (8, 18). The
amino acid sequence of the region shown to bind heparin is
highly basic and contains two short sequences that correspond
to consensus heparin-binding motifs that are found in many
structurally unrelated heparin-binding proteins, including antithrombin III, thrombin, low density lipoprotein, and endothelial growth factor (19, 20).
Although the sequence spanning residues 345–379 has been
localized as a primary heparin recognition site, some workers
have suggested that the charged sequence near the C terminus
may not be solely responsible for heparin affinity. A report
utilizing phage display indicates that sequences N-terminal to
the cationic cluster may contribute to binding heparin (21).
Specifically, phagemid particles displaying the peptides Asp82Cys137 and Lys175-Asp219 bound to heparin-agarose and to heparin immobilized on a microtiter plate. Also, recent work (22) in
which nominal “domains” in vitronectin were expressed as fusion
proteins with glutathione S-transferase indicated that the first
hemopexin repeat in vitronectin exhibited some heparin binding activity. However, neither of these studies characterized
affinities of the recombinant polypeptides for heparin.
There has been controversy about the degree of exposure of
the heparin-binding sequence in native vitronectin. It was originally assumed that the heparin-binding sequence was encrypted in the native fold of the molecule (19), but more recent
work from this laboratory has demonstrated that the heparinbinding site is fully exposed in native vitronectin (23). Confusion over the degree of exposure of sites within the conformationally labile protein had stemmed primarily from the
application of varied preparation protocols that produce
vitronectin forms that differ in oligomeric state. Also, the solidphase assays in widespread use for measuring heparin binding
are inadequate to distinguish changes in affinity from changes

in numbers of binding sites (23, 24). Solution binding measurements of heparin with different forms of vitronectin underscore
the importance of a rigorous determination of both binding
strengths and numbers of binding sites for a proper understanding of the heparin-vitronectin interaction (23, 24). Only
with both pieces of information was it possible to show the
exposed orientation of the heparin site, with comparable affinities for both the native and altered forms of vitronectin.
Is it correct to assume that all of the sequence information
necessary for heparin binding is present within the cationic
sequence near the C terminus of vitronectin? Does liberation of
the heparin-binding sequence from N-terminal sequences in
vitronectin support the argument that the heparin-binding
sequence is exposed in native vitronectin? Just as it has been
critical to use quantitative measurements to demonstrate the
exposed orientation of the primary heparin-binding site on
vitronectin, it is important to use rigorous methods to address
these questions critically. A variety of approaches, including
solution binding analyses, NMR, and recombinant methods,
were used to address these issues. According to these studies,
the relative importance of secondary glycosaminoglycan-binding sites on vitronectin appears to be minimal.
EXPERIMENTAL PROCEDURES

Materials—Vitronectin was purified from human plasma by a modification of the original protocol of Dahlback and Podack (25), as described (26). Human thrombin and antithrombin were generously provided by Dr. Frank C. Church (Department of Hematology, University
of North Carolina, Chapel Hill, NC). Synthetic peptides derived from
the sequence of the heparin-binding region of vitronectin were obtained
from Chiron Mimetopes. The peptides were more than 85% pure and
were used without further purification. Heparin fractions from porcine
mucosa with average molecular weights of 3000, 6000 and 15,000
(Grade 1-A) and the glycosaminoglycans, dextran sulfate, heparan sulfate, and fucoidan, were obtained from Sigma. Polyclonal antibodies
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against human vitronectin were produced at Rockland Laboratories.
Goat anti-rabbit IgG linked covalently with horseradish peroxidase was
obtained from Vector Laboratories. Chromozym-TH was purchased
from Boehringer Mannheim. Urea was obtained from ICN. All other
chemicals were of the highest grade commercially available and were
used without additional purification. Heparin labeled with the fluorescent coumarin probe was prepared as described previously (23).
Expression and Purification of the Recombinant C-terminal Domain
(rCTD)—The cDNA for human vitronectin (27) was obtained from Dr.
Erkki Ruoslahti (The Burnham Institute, La Jolla, CA) and cloned into
pT7-7 (28). Using an intrinsic NcoI site in the vitronectin sequence and
a 39 HindIII site from pT7-7, the DNA coding for residues Met330 to
Leu459 was cloned into the pET23d (Novagen) expression vector. In this
recombinant vector, transcription was under control of the T7 promoter,
with an internal methionine (Met330) from the vitronectin sequence
serving as a start codon for translation of the recombinant protein,
rCTD. The recombinant plasmid was transformed into competent
BL21(DE3)pLysS cells (Novagen). Transformants were grown to midlog phase in LB containing 50 mgzml21 ampicillin and 34 mgzml21
chloramphenicol, followed by induction with the addition of isopropylthiogalactoside to 1.0 mM. Cells were harvested 8 –16 h post-induction
by centrifugation; total cell lysates were analyzed by gel electrophoresis
on a 15% SDS-polyacrylamide gel stained with Coomassie Brilliant
Blue. The recombinant vitronectin polypeptide fragment was detected
by Western blot analysis using a polyclonal antiserum for vitronectin.
For purification, the rCTD was expressed in 250 ml of LB cultures
after induction with isopropylthiogalactoside. Cells were harvested after overnight growth at 37 °C by centrifugation, and cell extraction was
performed by freeze-thaw, with the addition of a sonication step (three
10-s bursts at the highest intensity) after each freeze-thaw cycle. After
centrifugation, the pellet was resuspended in 1/10 the original culture
volume with 8 M urea in HCB (20 mM Tris, 20 mM NaCl, 0.1 mM EDTA,
pH 7.4) and applied to a heparin-Sepharose column. The column was
washed sequentially with the denaturing HCB containing 20 mM NaCl
and 0.15 M NaCl. Purified rCTD was eluted in denaturing HCB buffer
containing 1.0 M NaCl. Fractions were analyzed for purity by SDSpolyacrylamide gel electrophoresis. The purified recombinant fragment
of vitronectin was stored at pH 4.0, conditions under which it exhibited
optimal solubility, following dialysis into either Glycine buffer (0.1 M
glycine, 0.15 M NaCl, pH 4.0) or Acetate buffer (0.1 M sodium acetate,
0.15 M NaCl, pH 4.0). In the presence of heparin, the rCTD was also
highly soluble at neutral pH.
Equilibrium analytical ultracentrifugation was used to evaluate the
size of the purified recombinant protein. Experiments were performed
using a Beckman Optima XL-A or Optima XL-I instrument, essentially
as described (29). The best fit of the data observed for rCTD in Acetate
buffer indicates that the protein is a mixture of oligomeric forms, predominantly an approximate 60,000 molecular weight species, with a minor
component that is more highly aggregated. The molecular weight for the
rCTD monomer was calculated from the amino acid sequence to be 15,100.
Fluorescence Spectroscopy for Binding Measurements—Vitronectin
binding to heparin was measured by fluorescence spectroscopy, using a
molecular weight-fractionated heparin sample that had been labeled
with a coumarin probe according to the method described by Zhuang et
al. (23). For experiments designed to measure salt-induced dissociation
of heparin from vitronectin, the binary complex was formed initially by
mixing vitronectin and coumarin-labeled heparin in equal concentrations of 2 mM in 2 ml of 20 mM sodium phosphate, pH 7.4. The fluorescence of the coumarin probe in the complex was measured at 480 nm
using an excitation wavelength of 430 nm. Small volume aliquots of a 5
M NaCl solution in the same buffer were added, and the fluorescence
emission intensity was again recorded. Aliquots of NaCl were added
until the fluorescence emission intensity had reached a plateau at
values that were nearly equivalent to those measured for coumarinheparin in the absence of added vitronectin.
Competition of dextran sulfate, heparan sulfate, or fucoidan for heparin binding to vitronectin was measured by displacement of bound
coumarin-labeled heparin from vitronectin. The fluorescence of a mixture of 5 mM labeled heparin (Mr ;6000) and 5 mM vitronectin (150 ml
total volume) was measured as the starting point (Fmax) in the competition experiments. Fluorescence was then recorded as aliquots of concentrated solutions of glycosaminoglycans (625 mM dextran sulfate, 200
mM fucoidan, or 690 mM heparan sulfate) were added to the cuvette so
that the added volume was no greater than 15%. Fluorescence emission
measurements (F) were taken at 480 nm with the excitation monochromator set at 430 nm. The F obtained was averaged for three measurements and corrected mathematically for dilution. Data were analyzed

as described (23, 30) using Equation 1 to give estimates of binding
affinity and stoichiometry for the competing ligands.

S D

Ki 1 2 a
1
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5
1
@VN#9 2 @VN#
l z Kd
a
l

(Eq. 1)

where [unlabeled-GAG] is the total concentration of competing unlabeled glycosaminoglycan; ([VN]9 2 [VN]) is the difference in the total
concentration of vitronectin required to achieve the same level of saturation in the presence of the competing ligand and in its absence; Kd and
Ki are the dissociation constants for the labeled heparin and competing
glycosaminoglycan, respectively; l is the binding stoichiometry; and a is
the fractional saturation. Data at values of a . 0.12 were analyzed
according to the equation. The Kd and l for interaction of vitronectin
with labeled heparin were determined previously to be 5.4 mM and 1,
respectively (23).
Changes in intrinsic tyrosine fluorescence were used for measurements of peptide binding to heparin. Fluorescence spectra were recorded using a Perkin-Elmer model LS-5B at room temperature with a
2-ml sample and 1-cm path length cells. Peptide was diluted to a final
concentration of 5 mM in 50 mM HEPES buffer, pH 5.0. Small volume
aliquots of heparin were added, and the fluorescence emission (F) at 305
nm (10-nm slit width) was recorded using an excitation wavelength of
275 nm and a 5-nm slit width. Fluorescence data were mathematically
corrected for dilution upon addition of titrant. The data were expressed
as DF/F0 in which DF 5 F 2 F0, and F0 was the starting fluorescence of
the sample. The values for DF were plotted as a function of vitronectin
concentration and were fit to Equation 2 using nonlinear least squares
analysis as follows:
DF 5 DFmax/2R*~R 1 T 1 Kd 2 ~~R 1 T 1 Kd!2 2 4TR!1/2!

(Eq. 2)

where R is the peptide concentration; T is the total heparin concentration; and Kd is the dissociation constant. The same equation was also
used to give an estimate for the stoichiometry of binding of the rCTD to
heparin for the titrations using intrinsic fluorescence of the rCTD, as
described below.
Heparin binding to the rCTD was measured by monitoring changes
in the intrinsic tryptophan fluorescence of the proteins upon addition of
small volume aliquots of heparin. Fluorescence measurements were
made using a quartz cuvette (Hellma) with a 1-cm path length using a
Perkin-Elmer LS50B luminescence spectrometer. To minimize protein
adsorption, the cuvettes were coated with lipids (31, 32), and the titrations were performed at low pH, where the recombinant protein was
optimally soluble. Protein samples (350 nM) in a total of 1.0 ml of 0.1 M
Acetate buffer, pH 4.0, containing 0.15 M NaCl and 0.1% polyethylene
glycol-8000 were titrated with small volumes of highly concentrated
solutions of heparin. The tryptophan fluorescence was measured after
each addition using an excitation wavelength of 290 nm, with the
emission wavelength set at 340 nm. The intensity of fluorescence (F)
recorded was the average of three readings. Control titrations of heparin into buffer in a reference cuvette were used to obtain F0 values. The
data were plotted as a function of titrant concentration and fit to the
Hill equation (Equation 3) using nonlinear least squares analysis.
DF/F0 5 ~DFmax/F0*@S#n!/~~K0.5!n 1 @S#n!

(Eq. 3)

where S is the total titrant concentration; K0.5 corresponds to the titrant
concentration at half-maximal saturation; and n is the Hill coefficient.
Cyanogen Bromide Mapping of HOCGO-labeled Vitronectin—
Vitronectin was labeled with HOCGO as described previously (33). The
labeled protein was digested with cyanogen bromide as described by
Suzuki et al. (4). Peptides were purified by reversed-phase high pressure liquid chromatography on a Phenomenex Jupiter C18 column
(4.6 3 250 mm) using a Beckman System Gold instrument for gradient
programming and data collection. Peptides generated by cyanogen bromide treatment were separated at a 1 ml/min flow rate in a three-step
gradient, running from 0 to 40% solvent B over 10 min, 40 –70% B over
the next 30 min, and then 70 –100% B in the final 20 min. Solvent A
contained 0.1% trifluoroacetic acid in water, and solvent B contained
0.1% trifluoroacetic acid in acetonitrile. The fractions were monitored at
220, 280, and 370 nm (for the HOCGO chromophore), and the peaks
were collected manually. Automated peptide sequencing was performed
at the sequencing facility of the University of Tennessee Medical Center, Knoxville, TN, by the Edman degradation method using an instrument from Applied Biosystems, Inc.
Sample Preparation for NMR Studies—Synthetic peptides were dissolved in 90% H2O, 10% 2H2O in a total volume of 500 ml yielding a final
concentration of 9 mM. The pH of the sample was adjusted to 5.0 6 0.1
to reduce exchange rates for exchangeable protons. Peptides were deu-
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FIG. 2. Ionic strength dependence of the heparin-vitronectin interaction. A, an initial complex between vitronectin and coumarinheparin was formed by mixing equimolar concentrations of protein and labeled heparin in phosphate buffer without NaCl, as described under
“Experimental Procedures.” Dissociation of the heparin-vitronectin complex by addition of NaCl was measured by the decrease in fluorescence
intensity of the coumarin probe attached to heparin. Fluorescence intensity data (F) are expressed relative to the initial fluorescence of the probe
in the complex (F0) as a function of added NaCl, plotted on a logarithmic scale. B, data from equilibrium binding measurements using
coumarin-labeled heparin (23) are plotted as a function of ionic strength. The slope of this plot, equal to 0.99, is indicative of the number of ionic
interactions involved in binding.
terated by repeated lyophilization and dissolution in 2H2O for studies
involving nonexchangeable protons only. The pH values of the solutions
in 2H2O are reported without correction of the pH-meter readings. A
heparin-peptide complex was prepared by adding heparin in a single
addition to give a final heparin concentration in slight excess over that
of the peptide.
NMR Spectroscopy—All 1H NMR spectra were recorded on a wide
bore Bruker AMX 400 spectrometer operating at 400 MHz for protons.
Standard two-dimensional 1H-1H COSY, DQF COSY, NOESY, and
HOHAHA (34 –36) data sets were collected in the phase-sensitive mode
using the time proportional phase increment method (37). 2K data
points were recorded in t2 for each of 221–364 t1 values, with 128
transients per t1 increment. The spectral width was 4032 Hz. The
HOHAHA pulse program contained an MLEV 17 spin lock sequence
(34) which was preceded and followed by two 2.5-ms trim pulses.
NOESY spectra were recorded with mixing times of 200, 250, 300, and
400 ms. All mixing times were varied randomly by 5%. HOHAHA
experiments were recorded with 4 mixing times ranging from 24.2 to
101 ms (including trim pulses). The data were zero-filled to 1K points in
t1 and were multiplied by a shifted sin (for COSY) or (sin)2 (for NOESY,
ROESY, HOHAHA) window function before Fourier transformation.
Phase corrections and base-line corrections were performed in both
dimensions.
Kinetic Analysis—The rate of inactivation of thrombin by the protease inhibitor, antithrombin, in the presence of heparin was measured
continuously using the chromogenic thrombin substrate, Chromozym-TH (38). Reactions were performed in a 1-ml reaction volume in
acrylic cuvettes (Sarstedt) at 23 °C in a buffer of 40 mM sodium phosphate, pH 7.4, containing 0.15 M NaCl and 0.1% polyethylene glycol8000. Heparin with an average molecular weight of 6,000 was used in
the reactions at a concentration of 66.0 nM. The initial concentrations of
Chromozym-TH, thrombin, and antithrombin were held constant at
0.19 mM, 2.0 nM, and 60.0 nM, respectively. Varying concentrations of
rCTD in 8.0 M urea were mixed with heparin prior to dilution into the
reaction mixture in order to ensure solubility. The urea concentration
was maintained at 0.8 M for all reactions by adding necessary volumes
of 8.0 M urea. Pseudo-first order rates of reaction (Kapp) were determined by non-linear least squares analysis using the IGOR software
package (Wavemetrics, Oswego, OR). These data were plotted against
the concentration of vitronectin or rCTD, and the Ki was determined
from the concentration of vitronectin that reduced the Kapp by 50%. The
Ki values for plasma-derived vitronectin were the same in 0 and 0.8 M
urea, indicating that the low urea concentration used in the assay did
not affect the interaction between heparin and vitronectin. Additionally, unfolding studies indicate that vitronectin structure is not affected
at this low urea concentration (26, 29).
RESULTS

In an attempt to more thoroughly evaluate the types of
interactions that characterize binding of human plasma
vitronectin to heparin, a multi-faceted approach was used that
combined solution biochemistry, spectrometry, and recombi-

nant approaches. Experiments were designed to evaluate ionic
versus non-ionic interactions in this context, to identify potential residues that contribute to the interaction, and to assess
further the extent to which the primary heparin-binding sequence is exposed on the surface of vitronectin.
Evaluation of the Ionic Strength Dependence of Heparin
Binding to Native Vitronectin Indicates a Single Ionic Interaction to Be Important—Recently, a quantitative method that
uses changes in the fluorescence of an extrinsic probe on heparin to measure the affinity and stoichiometry of heparin binding to vitronectin has been reported from this laboratory (23).
The assay has proven to be extremely informative and has
indicated that the heparin-binding site in native vitronectin is
exposed and functional, arguing against the “cryptic” orientation that had originally been proposed on the basis of more
qualitative measurements. In this study, the fluorescence assay was employed to systematically evaluate the ionic strength
dependence of the binding interaction and evaluate the number
of charged interactions that contribute to the binary interaction between heparin and vitronectin. As shown in Fig. 2A, the
binding of heparin to vitronectin is a sensitive function of ionic
strength, and modest salt concentrations completely displace
heparin from the protein. Fig. 2B shows a treatment of the
equilibrium binding data measured at different ionic strengths
according to classical linkage theory (39, 40). The slope of the
curve presented in Fig. 2B is equal to ;1, indicating the contribution of one ionic interaction to the overall binding free
energy at physiological pH. This result contrasts with similar
measurements for heparin binding to antithrombin III, in
which 5– 6 ionic interactions are involved in binding (41). This
difference has practical consequences, as antithrombin III has
an affinity for heparin that is at least 2 orders of magnitude
higher, and it binds to a heparin affinity column at much
higher ionic strengths than observed for vitronectin (42).
Sulfated Glycosaminoglycans That Bind to Vitronectin Compete with Heparin for the Binding Site—Other investigators
have shown that vitronectin exhibits affinity for certain highly
sulfated glycosaminoglycans, including dextran sulfate and fucoidan, in addition to heparin (43, 44). These ligands were
tested as competitors with heparin in the fluorescence assay for
binding to vitronectin. As shown in Fig. 3, both of these glycosaminoglycans are fully competitive with heparin for binding to
vitronectin. At fairly low concentrations, both ligands displace
heparin from vitronectin so that the fluorescence of the labeled
heparin is indistinguishable from the fluorescence measured in
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FIG. 3. Binding of other glycosaminoglycans to vitronectin is measured by displacement of labeled heparin in the fluorescence
assay. Mixtures of 5 mM coumarin-labeled heparin (Mr ;9300) and 5 mM vitronectin were titrated with unlabeled glycosaminoglycans. Displacement curves for dextran sulfate (Œ), fucoidan (l), heparan sulfate (f), and unlabeled heparin (●) are shown in A. The linear plots based on
Equation 1 for determination of binding affinities and stoichiometries are shown in B for dextran sulfate (Œ), fucoidan (l), and unlabeled heparin
(●). Only data corresponding to a .0.12 were analyzed, with the starting fractional saturation under these conditions equal to 0.37. The data for
heparan sulfate could not be analyzed adequately because binding was too weak to give complete displacement of the labeled probe. The plots in
B indicate that unlabeled heparin binds with a Kd of 6.3 mM and an l of 1.1; dextran sulfate binds with a Kd of 0.4 mM and an l of 0.9; and fucoidan
binds with a Kd of 0.06 mM and an l of 0.25. The results are calculated using the known binding constant of 5.4 mM and stoichiometry of 1 for the
labeled heparin sample determined previously (23). These values were used to generate the non-linear fits to Equation 1 for the data shown in A
for dextran sulfate, heparin, and fucoidan. The curve through the heparan sulfate data in A is for illustrative purposes only.

the absence of added protein (Fig. 3A). Analysis of these data
for binding affinities and stoichiometries as described previously (23, 30) indicated tighter binding to vitronectin of both of
the highly sulfated glycosaminoglycans, with Kd values of 0.4
and 0.06 mM for dextran sulfate and fucoidan, respectively,
compared with ;5 mM for heparin (Fig. 3B). The stoichiometry
of binding of dextran sulfate (Mr;8000) to vitronectin is 1:1,
whereas the stoichiometry of fucoidan (Mr;50,000):vitronectin
binding is 1:4. Thus, the larger polysaccharide exhibits more
binding sites for the protein, a property that is a straightforward function of the size of the glycosaminoglycan (45). More
important is the conclusion from these analyses that binding of
these ligands involves only a single class of binding sites, as the
model described in Equation 1 with only a single binding site
affinity gives adequate fits to the data in Fig. 3A. This result is
compatible with the fact that all previous analyses from this
laboratory for binding of heparin to vitronectin have been adequately modeled with only a single class of sites on the protein
(24).
Also shown in Fig. 3A are competition data for heparan
sulfate binding and displacing heparin from vitronectin. Heparan sulfate has previously been shown to have weaker effects
on vitronectin immunoreactivity or structure compared with
the more highly sulfated glycosaminoglycans (43, 44). These
data indicate a weaker affinity for vitronectin since heparan
sulfate does not completely displace heparin from the protein at
the concentrations used in these experiments.
Critical Arginine(s) That Affect Heparin Binding Are Localized within a Cyanogen Bromide Fragment That Contains the
C-terminal Cationic Cluster—The primary heparin-binding sequence within vitronectin has been localized by proteolysis and
studies with synthetic peptides (5, 17) to the sequence from 341
to 380. This region identified includes the 18-residue sequence,
(346)LAKKQRFRHRNRKGYRSQ(363), exhibiting a pattern of
cationic amino acids that aligns with consensus heparin-binding sequences derived from comparison of a large number of
heparin-binding proteins (19, 20). In a previous study to test for
specific arginine residues involved in the interaction, vitronectin was reacted with an arginine-specific coumarin reagent
(33). Labeling of 1–2 arginines in vitronectin impairs heparin
binding (33). Peptide mapping has now been used to identify
the region of the protein that is labeled. Cyanogen bromide,

which was originally used to identify the fragment-(340 –381)
as the heparin-binding region (5, 17), was added to digest
labeled vitronectin, and the digestion fragments were separated by reverse-phase high pressure liquid chromatography
(data not shown). Sequencing of the eluted fragments shows at
least 80% of the total label from the reaction is found within the
heparin-binding region on the 340 –381 fragment. When
vitronectin was labeled with the coumarin probe in the presence of heparin, there was much less incorporation of label, and
the quenching behavior of the probes was different compared
with the exposed label on the heparin-binding region (33).
These studies support other work from this laboratory in the
following ways: by demonstrating the accessibility (and thus
surface orientation) of the reactive arginines, by providing separate evidence for the contribution of only a small number of
arginine residues to the ionic interaction with heparin, and by
localizing these residues to the C-terminal cationic cluster.
Because of the challenge of identifying which of the numerous
arginines within the 340 –381 fragment contain the coumarin
label by standard peptide mapping approaches, an NMR analysis was pursued to evaluate a potential role of individual
amino acids in heparin binding.
Peptides Derived from the Primary Heparin-binding Site
Were Characterized by NMR—Synthetic peptides derived from
the primary heparin-binding region within vitronectin have
been used extensively to delineate structure-function relationships in the protein, and two such peptides were characterized
using NMR approaches in this study. Fig. 4 lists the sequences
of several peptides that have been used in mapping functional
sites on vitronectin, including the 40-amino acid peptide originally isolated as a heparin-binding cyanogen bromide fragment (4) and the consensus heparin-binding motifs derived
from sequence analyses of members within a family of heparinbinding proteins. The two peptides used in this study are listed
at the bottom of the figure for comparison with the various
sequences. The first of these peptides, PEPTIDE 1, is an 18residue sequence that encompasses peptides that have been
widely used in vitronectin structure-function work (5, 17, 46,
47). It contains both of the consensus sequences derived by
Cardin and Weintraub (20), as well as the single consensus
motif reported in the work of Sobel et al. (19). Note that the
18-mer is both highly charged and highly redundant in se-
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FIG. 4. Sequences of peptides derived from the heparin-binding region of vitronectin. Consensus sequences derived for heparinbinding regions from a family of proteins are given at the top of the figure, with B representing a basic amino acid (lysine, histidine, or arginine)
and X representing a non-basic amino acid. Amino acids within the sequence of vitronectin that correspond to consensus residues are highlighted
in bold. The 40-residue sequence in the center of the figure represents the cyanogen bromide fragment spanning residues 341–380 within the
sequence of human vitronectin that was shown to bind to heparin by affinity chromatography (4). Peptide a was used as a competitor for heparin
binding in kinetic studies measuring the heparin-promoted inhibition of factor Xa by antithrombin. Peptides b and c were observed to bind heparin
in solid-phase assays. The two sequences (PEPTIDES 1 and 2) that are listed at the bottom of the figure are characterized in this study. Amino
acid substitutions that were made within the sequence of PEPTIDE 2 are underlined (see text). Citations referenced in the figure are as follows:
1
Sobel et al. (19); 2Cardin and Weintraub (20); 3Suzuki et al. (4); 4Preissner et al. (17); 5Lane et al. (46); 6 Kost et al. (5); 7Stockmann et al. (47).

quence, containing 5 arginine residues, 1 histidine residue, and
3 lysine residues.
One-dimensional proton NMR and two-dimensional spectra
(NOESY and COSY, data not shown) were collected on the
18-residue peptide sample. Not surprisingly, the analyses were
not adequate to provide sequence-specific assignments for the
multiple charged residues in the peptide. Another impediment
to evaluating heparin-binding properties of the peptide was the
formation of an insoluble aggregate upon addition of ligand.
Attempts to minimize precipitation of the heparin-peptide complexes by modifying pH and ionic strength conditions were
unsuccessful. The formation of an insoluble aggregate in this
work with PEPTIDE 1 calls into question earlier work with
some of the other peptides (e.g. peptide a in Fig. 4 (17, 46)) in
which tight binding affinity for heparin was reported. Since
there is not a ready equilibrium between solid and solution
phases, true binding affinities cannot be calculated under these
conditions and will be artifactual in nature.
Because of these technical obstacles and the inability to get
sequence-specific information from the highly redundant sequence, the NMR characterization was focused on the 14-residue peptide listed in Fig. 4 as PEPTIDE 2. This peptide includes only one of the two consensus heparin-binding motifs
and contains less dense positive charge, with two lysines, two
arginines, and one histidine. The 14-mer also incorporates strategic replacements. (i) At positions 1 and 13 in PEPTIDE 2,
arginines are replaced by glycine and alanine, respectively.
Note that the arginine residue replaced at either position does
not correspond to a basic residue in any of the consensus
sequences listed. These substitutions were made in the sequence with the intention of simplifying the sequence-specific
assignments in the NMR work by reducing the redundancy of
amino acids in the peptide. It was reasoned that alanine and
glycine can be accommodated in any given secondary structure
that would be optimal for the sequence. (ii) Furthermore, the
replacement of tyrosine for phenylalanine at position 13 is a
conservative replacement that was introduced to provide an
intrinsic fluorescent probe within the sequence of the peptide.
Heparin binding to PEPTIDE 2 did not give the problematic
aggregation observed with PEPTIDE 1, and a Kd for the interaction with PEPTIDE 2 was estimated by fluorescence spectroscopy. Using the internal tyrosine in the 14-residue peptide
from vitronectin as a fluorescent probe to monitor heparin

binding gave an enhancement in fluorescence of the tyrosine
that clearly titrates as the peptide becomes saturated with
ligand (Fig. 5). Fitting of the binding isotherm, as shown by the
smooth curve in the figure, resulted in a dissociation constant of
150 mM for the interaction of heparin with the peptide. Low
molecular weight heparin was used in this experiment to minimize the potential for binding of multiple peptide sequences to
a single heparin chain, and the fitting of the data indicates a
1:1 stoichiometry of binding.
One-dimensional NMR, combined with COSY, HOHAHA,
NOESY, and ROESY experiments, provided sequence-specific
assignments for the majority of the protons in PEPTIDE 2
(data not shown). There was little chemical shift dispersion
observed in the C-aH and upfield regions of the NMR spectra of
the peptide, suggesting a random conformation of the peptide
in solution. This result is not particularly surprising given the
high density of positive charge that would lead to repulsion and
oppose adoption of an ordered, collapsed structure. The specific
assignments of the charged residues were much more successful with this peptide compared with PEPTIDE 1. However,
site-specific assignments were not achieved for the two lysine
residues, as chemical shifts for all protons on these residues
were indistinguishable in NMR spectra. Similarly, the C-b
proton of leucine and the side chain NHs of the two arginines
were not differentiated due to resonance overlap.
NMR Analysis of the Complex between Heparin and the Peptide Indicates Charged and Uncharged Residues to Be Involved
in the Binding Interaction—One-dimensional spectra (data not
shown) indicated that there is very little spectral overlap between the peptide and heparin, thus providing a favorable
situation for studies on the heparin-peptide interactions by
NMR. Upon addition of saturating heparin concentrations, the
one-dimensional spectrum exhibited changes in the region of
the arginine C-dH and lysine C-eH proton chemical shifts (3.0 –
3.3 ppm), which indicate that one or more basic residues are
affected by the formation of the heparin-peptide complex. The
intensity of the resonance at 3.3 ppm decreased, indicating that
an arginine C-dH group is shifted downfield under the heparin
resonances or broadened in the binary heparin-peptide complex. In concert with these observations, the side chain NH
resonances of arginine and lysine residues were also affected
strongly, suggesting that the exchange rates of these protons
were altered significantly. Furthermore, both the C-2 and C-4
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FIG. 5. Heparin effect on the fluorescence of PEPTIDE 2. Small
volume aliquots of heparin were added to 2-ml solutions of peptide in 50
mM HEPES buffer, pH 5.0. The solid line represents the binding curve
determined by non-linear least squares analysis to Equation 2, as
described under “Experimental Procedures.”

protons of histidine (at 8.6 and 7.35 ppm, respectively), as well
as tyrosine side chain protons (6.8 and 7.1 ppm), exhibit linebroadening. Other changes observed in the a-NH region and
broadening of asparagine C-bH (2.8 ppm) and glutamine C-gH
(2.36 ppm) resonances indicate that multiple interactions occur
between the peptide and heparin in the complex. Concomitantly, a downfield shift of the C-bH resonance of glutamine
(2.05 ppm) is observed.
The expanded amide/aliphatic region of the NOESY spectra
recorded with the peptide-heparin complex at 300 K is shown
in Fig. 6. Two marked NOE cross-peaks in the NOESY spectrum of the binary complex most likely represent intermolecular NOEs from heparin to the following: (i) the C-dH of arginine
(marked A) and (ii) the a-NH of glutamine or arginine 9
(marked B). In contrast to this, in the spectra recorded with
peptide alone, only a few cross-peaks corresponding to sequential H-ai/NHi11 interactions and NH-CH side chain interactions were observed, and their intensities were barely above
the noise level. Addition of heparin gives rise not only to new
cross-peaks but also increases the intensity of some of the
observed NOEs that correspond to NH/side chain and intermolecular interactions.
Heparin Binds with High Affinity to a Recombinant C-terminal Domain (rCTD)—To complement the equilibrium binding
measurements, peptide mapping and detailed spectrometry, a
recombinant fragment of vitronectin was cloned into an expression vector to allow facile production in a prokaryotic system.
The C-terminal 129 amino acids were selected for expression to
encompass the primary heparin-binding site identified in
vitronectin within the context of the second hemopexin domain.
The recombinant polypeptide expressed in this work differs
somewhat from the “hemopexin 2” domain expressed and partially characterized recently (22), as the rCTD is 60 amino acids
shorter in sequence, beginning further downstream at methionine 331 so that it is missing vitronectin residues 270 –330.
Another major difference between the constructs is that the
rCTD used in this work is not a fusion protein, whereas the
hemopexin 2 domain characterized by and Yoneda and coworkers (22) contained a large N-terminal glutathione S-transferase fusion. The oligomeric nature of the recombinant
polypeptide used in this work was explicitly determined by
analytical ultracentrifugation to be predominantly a tetramer.
Other recombinant fragments from vitronectin, such as the
fusion protein used by Yoneda et al. (22), have an unknown
oligomeric structure.
The region of vitronectin expressed in rCTD contains 3 tryptophans, providing convenient intrinsic fluorescent probes to

FIG. 6. An expanded region from the NOESY spectrum of the
peptide:heparin mixture. The spectrum for the peptide:heparin (9:10
mM) mixture was obtained at 300 K with a mixing time of 200 ms.
Intermolecular NOEs are marked as A and B.

monitor heparin binding to the recombinant protein. The fluorescence of rCTD was enhanced approximately 3-fold upon
addition of saturating concentrations of heparin. Titration data
are presented in Fig. 7 for three different sizes of heparin. The
stoichiometry of binding was observed to be dependent on heparin chain length. Variation in binding stoichiometry with the
size of heparin is a well established phenomenon observed with
full-length vitronectin (23) and other heparin-binding proteins
(45). The binding stoichiometry using low molecular weight
heparin (Mr ; 3,000) is approximately 1 mol of rCTD per mol
of heparin. When the heparin size is increased to 6000, the
stoichiometry increases to about 2 mol of rCTD bound per mol
of heparin, and approximately 6 rCTD bind to a heparin chain
with a molecular weight of 15,000.
A sigmoidal shape is noted in the binding curves, suggestive
of a cooperative interaction between the glycosaminoglycan
and the recombinant protein, which is a tetramer. The data
were therefore fit to a Hill equation. For large molecular weight
heparin, the K0.5 was calculated to be approximately 5 nM. This
value was somewhat larger for low molecular weight heparin,
indicative of weaker binding with smaller heparin chains. As
would be expected, the increased number of binding sites on
larger heparin molecules strengthens the binding affinity with
oligomeric rCTD. Control experiments measuring heparin
binding to full-length plasma vitronectin at pH 4.0 gave a
comparable Kd of 12 nM (data not shown).2 This pH was used
for the binding experiments with the rCTD to mimic conditions
that give optimal solubility of the recombinant protein in the
absence of heparin and ensure that there were no non-equilibrium or light scattering artifacts in the measurements. The
tighter binding to heparin observed below the pI of the protein
is a predictable function of the net positive charge on the
protein or polypeptide.
The Recombinant Heparin-binding Domain from Vitronectin
Neutralizes Heparin Anticoagulant Activity—Heparin binding
to the recombinant proteins was also measured using a kinetic
assay that has previously been employed to analyze vitronectin
binding to heparin. This assay is based on the ability of
vitronectin to compete with other proteins for binding to heparin (48). Thrombin is inactivated upon binding the serine
protease inhibitor, antithrombin. Although this reaction is nor2
The oligomeric state of plasma-derived vitronectin was determined
under acidic conditions (pH 4.0) by gel-filtration chromatography. Under these conditions vitronectin is predominantly monomeric.
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FIG. 7. Fluorescence changes in rCTD upon interaction with
heparin. The binding isotherms for heparin interacting with rCTD in
Acetate buffer are depicted. The fluorescence emission of 350 nM solutions of rCTD was measured at 340 nm (using an excitation wavelength
of 290 nm) following each addition of heparin. Note that the protein
concentration indicated on the x axis corresponds to the concentration
of monomeric subunits and therefore represents the concentration of
heparin-binding sites in solution. Binding to the protein sample was
analyzed using three different heparin stocks with average molecular
weights of 15,000 (circles), 6,000 (squares), and 3,000 (triangles). The
raw data were analyzed as described under “Experimental Procedures”
to obtain the values for DF. The data were normalized by dividing DF by
DFmax for each titration to obtain the fractional saturation values and
were fit using the Hill equation (Equation 3) to obtain the binding
isotherm shown (solid line).

mally slow, heparin increases the rate of reaction between
thrombin and antithrombin by several orders of magnitude.
However, molecules like vitronectin, which compete with the
protease and/or its inhibitor for heparin binding, can neutralize
the heparin-catalyzed inactivation of thrombin. The ability of
molecules to compete for heparin binding is measured by monitoring the rate of inactivation of thrombin by antithrombin in
the presence of heparin and testing increasing concentrations
of the competing molecule for effects on the rate. When the
rCTD was evaluated in this assay, it neutralized the heparincatalyzed inactivation of thrombin. The rate of inactivation of
thrombin decreased significantly and eventually reached a plateau upon the addition of high concentrations of recombinant
protein (Fig. 8). The Ki for the interaction is 0.3 mM with rCTD.
Plasma-derived vitronectin competes for heparin binding in the
same assay with a Ki of approximately 0.4 mM. These data
indicate that rCTD neutralizes the anticoagulant activity of
heparin as effectively as full-length plasma vitronectin. It is
apparent from these data that the elements critical for binding
and neutralizing heparin are present within the recombinant
C-terminal polypeptide.
DISCUSSION

There has been considerable discussion in the vitronectin
literature concerning the relationship between the structure
and function of the protein. Vitronectin is believed to be a
multifunctional protein with ligand-binding functions localized
to independent domains in the molecule. However, the large
size and conformational lability of vitronectin has precluded
structural characterization of the protein by crystallography or
NMR. In the absence of a three-dimensional structure, domain
assignments have been based on the ability of monoclonal
antibodies, synthetic peptides, or proteolytic fragments to compete with plasma-derived vitronectin for ligand binding.
The goal of this study was to elaborate on the domain model
for vitronectin, presented in Fig. 1. Aspects of the model that
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FIG. 8. Heparin neutralization by the rCTD and vitronectin.
Heparin activity was measured by an increase in the reaction rate of
antithrombin inactivation of thrombin. The concentration of active
thrombin was monitored continuously over time by hydrolysis of the
Chromozym-TH substrate as described under “Experimental Procedures.” The effects of the rCTD (squares) or plasma vitronectin (circles)
on the reaction kinetics were measured at varying concentrations and
are standardized to the reaction rate of heparin-catalyzed inhibition in
the absence of the vitronectin-derived polypeptide. The smooth curves
shown are for illustrative purposes only and do not represent mathematical fitting of the data.

merit further consideration include the following: (i) the identification of critical structural elements within the consensus
heparin-binding site for binding to glycosaminoglycans; (ii) the
relative importance of recently identified secondary heparinbinding sites; (iii) the potential for structural alterations in
multimeric vitronectin to influence the relative importance of
primary and secondary heparin-binding sites in the protein;
and (iv) the extent of exposure of the primary heparin-binding
site on the surface of native vitronectin, a point of some controversy since the historical model for vitronectin structure and
function had proposed a buried site (17). Toward these aims, a
more rigorous examination of glycosaminoglycan binding to
vitronectin in solution has been pursued. Furthermore, arginine residues within vitronectin that are modified with a fluorescent probe, resulting in a diminution of heparin binding
activity, have been localized by peptide mapping to the cyanogen bromide fragment containing the primary heparin-binding
site. Also, synthetic peptides that are based on this primary
heparin-binding site of vitronectin have been characterized by
NMR in isolation and in complex with heparin to give insight
into particular types of interactions that are important. Finally, a recombinant heparin-binding domain from vitronectin
has been thoroughly characterized according to heparin-binding properties and shown to bind the ligand with nearly identical affinity as that of plasma vitronectin. These results together have bearing on each of the aspects of the domain model
for vitronectin that have been raised for discussion.
What Are the Critical Structural Elements for Heparin Binding?—Previous work from this laboratory had demonstrated
that the dissociation constant for the binding of heparin to
vitronectin was dependent on ionic strength (23). If data are
analyzed to predict the number of ionic interactions that contribute to the binding of heparin to the protein, the result is
that only a single ionic interaction appears to be prominent for
binding of the ligand. This result is unexpected because the
primary heparin-binding sequence in vitronectin is argininerich so that more than one charged contact would be possible
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between the protein and ligand. However, this result is in
accordance with the observation that native vitronectin exhibits a fairly weak affinity for heparin (in the 5–10 mM range (23))
at low ionic strengths, and the affinity is diminished at physiological ionic strengths. It is also consistent with the observation from previous work that the modification of only 1–2
arginines impairs heparin binding to vitronectin (33). This
study has taken the previous observation a step further by
demonstrating that the fluorescent probe introduced in the
chemical modification experiments is localized to a cyanogen
bromide peptide fragment-(341–380) containing the primary
heparin-binding sequence.
A synthetic peptide derived from this primary heparin-binding sequence in vitronectin was studied by NMR as a model to
evaluate ionic and other interactions that contribute to proteinligand affinity. Indeed, although there are numerous possible
ionic contacts that might have been observed for the binary
complex, only a single charge-charge interaction is observed
from the NOESY analysis. An arginine residue is responsible
for this contact, although it is not possible from the spectra to
distinguish between the two arginines in the peptide (which
correspond to Arg351 and Arg353 in vitronectin). Valuable insight into the nature of the interaction was also gained from
the demonstration of other types of contacts with the peptide
involving nonionic interactions with glutamine or asparagine.
Note that these interactions are made via side chains rather
than the peptide backbone, indicating some degree of specificity conferred via these interactions that is not predicted by the
consensus motif that merely specifies basic versus nonbasic
amino acids within the sequence. Thus, binding strength also
appears to be a function of the context within which the consensus sequence is found. Glutamine, asparagine, and tyrosine
residues have been observed to contact ligands in the saccharide-binding sites of several other proteins (49).
The model peptide used in this study exhibited relatively
weak binding to heparin. It is common that isolated peptides
exhibit lower affinity for their ligands than intact proteins, and
this result presumably indicates that the bulk of the sequence
is important for maintaining the binding site in its proper
conformation. This 14-residue peptide was not sufficiently long
to adopt an ordered structure, although this region in the intact
protein is thought to assume a b-sheet conformation. Naturally, in addition to a conformational role, residues outside this
14-amino acid sequence could directly contribute to binding.
Because of the relatively weak binding exhibited by the
peptide and the inability to distinguish between multiple arginine residues by NMR, an alternative system for studying
heparin binding was a recombinant polypeptide containing the
C-terminal 129 amino acids from vitronectin. The rCTD was
capable of neutralizing heparin activity in a kinetic assay
measuring its ability to inhibit the heparin-catalyzed inactivation of thrombin by antithrombin. It can be concluded that all
elements necessary for heparin binding and neutralization are
present in the C-terminal 129 amino acids of vitronectin. The
rCTD now provides a model system for utilizing site-directed
mutagenesis in the future to unravel the structural details of
the interaction with heparin and other ligands that bind in this
region of vitronectin. Other ligands of interest include sulfated
lipids, which have been recently shown to interact in the vicinity of the heparin-binding region and to be competitive with
glycosaminoglycans for binding (22).
As with full-length vitronectin, the binding stoichiometry of
the rCTD-heparin interaction varied with heparin chain
length. Cardin and Weintraub (20) originally modeled the heparin-binding sequence of vitronectin with a heparin octasaccharide. Lane et al. (46) showed that the octasaccharide as well

as a pentasaccharide are neutralized by vitronectin. Using
heparin with approximately 10 saccharides, essentially one to
one binding was achieved with recombinant protein binding to
heparin. As the heparin chain was increased, to 20 and 50
saccharides, the stoichiometries increased to 2 and 6 (vitronectin per heparin chain), as would be expected if the vitronectinbinding site interacts with 8 saccharide units on a heparin
molecule. These data support the assumption that the vitronectin-binding site on heparin consists of approximately 8 saccharides. Consistent with this view, Lane et al. (46) reported that
6 mol of vitronectin are needed to completely neutralize the
anticoagulant activity of the 3rd International Heparin Standard (Mr ;15,000) against factor Xa. Other studies from this
laboratory indicate that the number of binding sites on heparin
for full-length plasma-derived vitronectin is somewhat lower
due to steric hindrance (23). By expressing the recombinant
CTD, without N-terminal sequences, maximal occupancy of the
vitronectin-binding sites (octasaccharides) on the heparin
chain is achieved.
Do Secondary Heparin-binding Sequences Contribute Substantially to the Affinity of Vitronectin?—It has been suggested
that sequences from the connecting region and the first hemopexin domain in vitronectin might also contribute to heparin
binding (21, 50). It is important to note that heparin affinity for
these recombinant peptides was not evaluated quantitatively
in the original reports, so there is little supporting evidence for
this contention. The study of Yoneda and co-workers (22) used
solid-phase heparin binding assays to compare binding of glutathione S-transferase fusion proteins containing the first hemopexin repeat and the second repeat (encompassing the primary heparin-binding site). There is at least an order of
magnitude difference in binding between the two sequences
from vitronectin, with weaker apparent binding to the first
hemopexin domain, but no comparison was made with purified
plasma vitronectin. With this in mind, it was important to
evaluate whether the primary heparin-binding site could account for the full extent of heparin binding activity.
As mentioned above, mathematical fits to the binding isotherms generated by the interaction of vitronectin with labeled
heparin have always been satisfactory with only a single class
of binding sites (23). Competition studies with other sulfated
glycosaminoglycans in this work give a similar result. The
binding of dextran sulfate or fucoidan to vitronectin completely
displaces the labeled heparin from the protein, and mathematical modeling of the system indicates only a single class of
binding sites. A separate line of evidence refuting the importance of a secondary binding site on vitronectin is the observation that chemically modified vitronectin generated using an
arginine-reactive probe exhibits a significant reduction in heparin binding upon the labeling of only 1–2 residues. In this
study, the label has been localized to arginine residues within
the cyanogen bromide fragment-(341–380). This is the same
polypeptide that was characterized in the original identification of the primary site containing consensus heparin-binding
motifs (4). Furthermore, the fact that a recombinant domain
from the C terminus of vitronectin and full-length plasmaderived vitronectin do not differ in their affinities for heparin
supports the idea that all of the structural elements needed for
heparin binding are present in the recombinant C-terminal
domain and obviates the need to consider secondary binding
sites as significant.
Do Secondary Heparin-binding Sequences Become Functional in the Altered Conformation of Vitronectin Adopted in the
Multimer?—With emerging biophysical and structural data,
researchers have come to appreciate the conformational flexibility of vitronectin, which exists primarily in a monomeric
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form in plasma but converts to a multimer that may resemble
the extracellular matrix conformation upon denaturation and
subsequent refolding (26, 29, 51). The prevailing theory has
been that vitronectin function is regulated by this conformational lability, with the molecule expressing different functional repertoires depending on its oligomeric state. A prominent interpretation of this model has been that the functional
domains described above vary in their degree of exposure,
depending on the conformational state of the molecule.
The recent work of Yoneda and colleagues (22) on recombinant fusion proteins representing hypothetical domains within
vitronectin has deviated somewhat from traditional lines of
thought about the conformational alterations in vitronectin.
Their studies demonstrate glycosaminoglycan binding to the
first hemopexin domain, albeit significantly weaker than observed with the second hemopexin domain that contains the
primary heparin-binding consensus site. This result is interpreted by these workers as a means of providing a second
heparin-binding site that can become functional in the conformationally altered form of vitronectin. In this scenario, the
secondary binding sequences are now the cryptic ones in the
native form of vitronectin. Note again that these measurements were performed using solid-phase technology and that
true ligand affinities cannot be derived from these data.
Furthermore, as the authors acknowledge, there is no direct
evidence for altered exposure of the secondary sites. Clearly,
more rigorous experimentation is needed to make this
determination.
Even so, work from this laboratory has clearly disputed a
buried orientation of the primary heparin site, and the evaluations of heparin-binding stoichiometry for the native and multimeric forms of vitronectin have bearing on this discussion.
Rather than inducing changes in affinity (or “exposure”) of the
primary binding site on vitronectin, denaturation and renaturation of vitronectin lead to a multimeric form of vitronectin
that binds to heparin with a different stoichiometry than the
native protein. The monomeric native protein exhibits 1:1 binding, but the multimer exhibits a 2:1 stoichiometry, in which two
vitronectin protomers within the multimer contact a single
heparin molecule. This multivalent binding gives apparently
tighter binding to heparin when measured by non-solution
methods (24). A critical point is that the 2:1 stoichiometry
represents two separate vitronectin protomers contacting a
single heparin molecule, rather than two different binding sites
within the same protomer contacting heparin. If the latter were
the case, then an actual reduction in stoichiometry would be
measured, i.e. the available vitronectin-binding sites on heparin would be saturated with a lower concentration of vitronectin protomers. That is, if there were a secondary heparinbinding site that became functional in the altered conformation
of vitronectin, a stoichiometry of 0.5:1 (vitronectin:heparin)
would be expected instead of the 2:1 stoichiometry observed.
These quantitative analyses argue against the contribution of
secondary sites to binding after unfolding of vitronectin. For
further consideration of the ways in which protein:ligand binding stoichiometries can be influenced by multiple binding sites
on either heparin or the protein, the reader is referred to
published work on antithrombin or thrombin binding to heparin (45, 52, 53).
Does Liberation of the Heparin-binding Region from N-terminal Sequences Alter Exposure of the Primary Binding Site?—
The data presented here are consistent with exposure of the
heparin-binding site on folded vitronectin. If interactions with
N-terminal sequences mask the heparin-binding site of
vitronectin, expression of the isolated C-terminal domain separate from upstream sequences should in effect “unmask” the

6441

heparin-binding site. Thus the binding affinity for recombinant
CTD should be higher than observed for intact plasma vitronectin. This is not the case. In two assays, the recombinant protein
showed similar affinity for heparin to monomeric plasma-derived vitronectin, contradicting the argument that interactions
with other residues mask the heparin-binding site.
This observation is consistent with other work from this
laboratory (23) that has revealed that both native and multimeric vitronectin bind heparin with the same affinity. The
alignment of multiple binding sites in multimeric vitronectin
increases their local concentration. In solid-phase assays, the
end result is that multimeric vitronectin appears to bind heparin more tightly than the native folded molecule. Solution
biochemistry indicates that differences in the binding of heparin to altered forms of vitronectin result from changes in binding stoichiometry due to the alignment of multiple heparinbinding sites on multimeric vitronectin, and not from
encryption of the binding site in native vitronectin. Also, observations that this region of the molecule is highly susceptible
to proteolysis by thrombin (18), plasmin (8, 18), and an endogenous protease that cleaves one allelic variant of vitronectin
between 379 and 380 (54) indicate that residues from the
heparin-binding region must be presented on the surface of
native vitronectin. Moreover, the susceptibility of native
vitronectin to phosphorylation at serine 378 (55, 56) and chemical modification of an arginine within the heparin-binding
sequence (33) corroborate the surface orientation of the heparin-binding site. Altogether, the data support the concept that
the C-terminal region of vitronectin is fully exposed in native
vitronectin and functions autonomously with respect to heparin binding.
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